KR102759974B1 - HER2 억제제로서의 [1,3]디아지노[5,4-d]피리미딘 - Google Patents

HER2 억제제로서의 [1,3]디아지노[5,4-d]피리미딘 Download PDF

Info

Publication number
KR102759974B1
KR102759974B1 KR1020227040861A KR20227040861A KR102759974B1 KR 102759974 B1 KR102759974 B1 KR 102759974B1 KR 1020227040861 A KR1020227040861 A KR 1020227040861A KR 20227040861 A KR20227040861 A KR 20227040861A KR 102759974 B1 KR102759974 B1 KR 102759974B1
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
following structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227040861A
Other languages
English (en)
Korean (ko)
Other versions
KR102759974B9 (ko
KR20230005263A (ko
Inventor
비르기트 빌딩
디트리히 보에세
하랄드 엥겔하르트
줄리안 푸쉬
랄프 뉴뮤엘러
마크 페트론츠키
더크 샤른
마티아스 트레우
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70470818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102759974(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Priority to KR1020257002191A priority Critical patent/KR20250016507A/ko
Publication of KR20230005263A publication Critical patent/KR20230005263A/ko
Application granted granted Critical
Publication of KR102759974B1 publication Critical patent/KR102759974B1/ko
Publication of KR102759974B9 publication Critical patent/KR102759974B9/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227040861A 2020-04-24 2021-04-07 HER2 억제제로서의 [1,3]디아지노[5,4-d]피리미딘 Active KR102759974B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257002191A KR20250016507A (ko) 2020-04-24 2021-04-07 HER2 억제제로서의 [1,3]디아지노[5,4-d]피리미딘

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20171221 2020-04-24
EP20171221.3 2020-04-24
PCT/EP2021/059015 WO2021213800A1 (en) 2020-04-24 2021-04-07 [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257002191A Division KR20250016507A (ko) 2020-04-24 2021-04-07 HER2 억제제로서의 [1,3]디아지노[5,4-d]피리미딘

Publications (3)

Publication Number Publication Date
KR20230005263A KR20230005263A (ko) 2023-01-09
KR102759974B1 true KR102759974B1 (ko) 2025-01-24
KR102759974B9 KR102759974B9 (ko) 2026-06-18

Family

ID=70470818

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227040861A Active KR102759974B1 (ko) 2020-04-24 2021-04-07 HER2 억제제로서의 [1,3]디아지노[5,4-d]피리미딘
KR1020257002191A Pending KR20250016507A (ko) 2020-04-24 2021-04-07 HER2 억제제로서의 [1,3]디아지노[5,4-d]피리미딘

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257002191A Pending KR20250016507A (ko) 2020-04-24 2021-04-07 HER2 억제제로서의 [1,3]디아지노[5,4-d]피리미딘

Country Status (33)

Country Link
US (3) US11608343B2 (cg-RX-API-DMAC7.html)
EP (2) EP4566611A3 (cg-RX-API-DMAC7.html)
JP (2) JP7260723B2 (cg-RX-API-DMAC7.html)
KR (2) KR102759974B1 (cg-RX-API-DMAC7.html)
CN (13) CN118388488A (cg-RX-API-DMAC7.html)
AR (1) AR121779A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021260721B2 (cg-RX-API-DMAC7.html)
CA (1) CA3173602A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002579A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022015054A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220537A (cg-RX-API-DMAC7.html)
DK (1) DK4139309T5 (cg-RX-API-DMAC7.html)
DO (1) DOP2022000189A (cg-RX-API-DMAC7.html)
EC (1) ECSP22072777A (cg-RX-API-DMAC7.html)
ES (1) ES3013860T3 (cg-RX-API-DMAC7.html)
FI (1) FI4139309T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250426T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070805T2 (cg-RX-API-DMAC7.html)
IL (2) IL320477A (cg-RX-API-DMAC7.html)
JO (1) JOP20220271A1 (cg-RX-API-DMAC7.html)
LT (1) LT4139309T (cg-RX-API-DMAC7.html)
MA (1) MA59373B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022013223A (cg-RX-API-DMAC7.html)
PE (1) PE20230827A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552745A1 (cg-RX-API-DMAC7.html)
PL (1) PL4139309T3 (cg-RX-API-DMAC7.html)
PT (1) PT4139309T (cg-RX-API-DMAC7.html)
RS (1) RS66557B1 (cg-RX-API-DMAC7.html)
SI (1) SI4139309T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500164T1 (cg-RX-API-DMAC7.html)
TW (1) TWI913256B (cg-RX-API-DMAC7.html)
UA (1) UA130588C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021213800A1 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
US20230126204A1 (en) * 2020-02-03 2023-04-27 Boehringer Ingelheim International Gmbh [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2022266458A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 6-heterocycloalkyl-quinazoline derivatives and uses thereof
EP4359082A1 (en) 2021-06-26 2024-05-01 Array BioPharma Inc. Her2 mutation inhibitors
EP4476211A4 (en) * 2022-02-09 2026-02-25 Enliven Inc ACYLIC HETEROCYCLIC QUINAZOLINE DERIVATIVES USED AS ERBB2 INHIBITORS
US20250206760A1 (en) 2022-03-28 2025-06-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
WO2023195773A1 (ko) * 2022-04-05 2023-10-12 보로노이 주식회사 헤테로아릴 유도체 및 이의 용도
CN117384162A (zh) * 2022-05-17 2024-01-12 浙江文达医药科技有限公司 选择性her2抑制剂
WO2024027695A1 (zh) * 2022-08-04 2024-02-08 微境生物医药科技(上海)有限公司 作为her2抑制剂的化合物
CA3263309A1 (en) 2022-08-22 2024-02-29 Iambic Therapeutics, Inc. HER2 COMPOUNDS AND MODULATION METHODS
AU2023410324A1 (en) 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
EP4637771A1 (en) * 2022-12-22 2025-10-29 Boehringer Ingelheim International GmbH Solid dispersion of a her2 inhibitor
US20260207606A1 (en) 2022-12-22 2026-07-23 Boehringer Ingelheim International Gmbh Dosing schedule of a solid dispersion of a her2 inhibitor
WO2024200637A2 (en) 2023-03-29 2024-10-03 Boehringer Ingelheim International Gmbh Dosing schedule of a her2 inhibitor
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
JP2026520494A (ja) 2023-05-31 2026-06-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がん処置の応答性を予測するためのバイオマーカーとしてのサバイビン
CN116903615A (zh) * 2023-06-21 2023-10-20 江苏丽源医药有限公司 一种妥卡替尼及其中间体的制备方法
CN121568696A (zh) 2023-07-28 2026-02-24 勃林格殷格翰国际有限公司 制备her2抑制剂的方法
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
EP4773966A1 (en) * 2023-09-06 2026-07-15 Boehringer Ingelheim International GmbH Cancer treatment with a her2 inhibitor and a cyp3a and/or p-gp modulator
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
US20250228858A1 (en) 2023-12-20 2025-07-17 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy
IL330174A (en) 2023-12-20 2026-08-01 Boehringer Ingelheim Int Gmbh Combination cancer treatment using zongratinib and KRAS G12C inhibitor
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202606709A (zh) * 2024-04-03 2026-02-16 德商百靈佳殷格翰國際股份有限公司 抗癌組合療法
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025257149A1 (en) 2024-06-11 2025-12-18 Boehringer Ingelheim International Gmbh Crystalline forms of zongertinib a her2 tyrosine kinase inhibitor
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
CN121270563A (zh) * 2024-07-01 2026-01-06 北京鞍石生物科技股份有限公司 稠环化合物及其制备方法和应用
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026027757A1 (en) 2024-08-02 2026-02-05 Boehringer Ingelheim International Gmbh Treatment of cancer with metastases in the central nervous system
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026077844A1 (en) 2024-10-07 2026-04-16 Boehringer Ingelheim International Gmbh Solid dispersions having stabilized emulsion particles
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032880A1 (de) 1996-03-06 1997-09-12 Dr. Karl Thomae Gmbh PYRIMIDO[5,4-d]PYRIMIDINE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG
WO2003049740A1 (en) 2001-12-12 2003-06-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
WO2005044302A1 (en) 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
WO2019042409A1 (zh) 2017-09-01 2019-03-07 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW414798B (en) * 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
US20070107957A1 (en) * 2005-11-16 2007-05-17 Lonnie Lehrer Automobile propulsion system
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CA2949793C (en) 2014-06-19 2024-02-27 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
US20210323976A1 (en) 2015-05-13 2021-10-21 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
AU2018325442B2 (en) 2017-08-31 2023-04-13 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and/or HER2 and methods of use
US20230126204A1 (en) 2020-02-03 2023-04-27 Boehringer Ingelheim International Gmbh [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
CN115052881B (zh) 2020-02-03 2024-07-09 勃林格殷格翰国际有限公司 作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
WO2021231400A1 (en) * 2020-05-12 2021-11-18 Accutar Biotechnology, Inc. Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032880A1 (de) 1996-03-06 1997-09-12 Dr. Karl Thomae Gmbh PYRIMIDO[5,4-d]PYRIMIDINE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG
WO2003049740A1 (en) 2001-12-12 2003-06-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
WO2005044302A1 (en) 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
WO2019042409A1 (zh) 2017-09-01 2019-03-07 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用

Also Published As

Publication number Publication date
CN118388488A (zh) 2024-07-26
IL297490A (en) 2022-12-01
CN118307543A (zh) 2024-07-09
CN118307544A (zh) 2024-07-09
MA59373B1 (fr) 2025-02-28
IL297490B1 (en) 2025-06-01
JP2023085489A (ja) 2023-06-20
RS66557B1 (sr) 2025-03-31
LT4139309T (lt) 2025-02-25
EP4566611A3 (en) 2025-09-10
HUE070805T2 (hu) 2025-07-28
CN118619956A (zh) 2024-09-10
PL4139309T3 (pl) 2025-05-05
CN118388493A (zh) 2024-07-26
JP2023512343A (ja) 2023-03-24
US11608343B2 (en) 2023-03-21
KR102759974B9 (ko) 2026-06-18
JP7260723B2 (ja) 2023-04-18
MX2022013223A (es) 2022-11-14
DOP2022000189A (es) 2022-09-30
PT4139309T (pt) 2025-02-17
US20250122204A1 (en) 2025-04-17
BR112022021514A2 (pt) 2023-01-24
CN118388492A (zh) 2024-07-26
EP4139309B1 (en) 2025-01-29
CN118388491A (zh) 2024-07-26
EP4566611A2 (en) 2025-06-11
AR121779A1 (es) 2022-07-06
ES3013860T3 (en) 2025-04-15
JOP20220271A1 (ar) 2021-10-28
CN118388487A (zh) 2024-07-26
CN118388489A (zh) 2024-07-26
SMT202500164T1 (it) 2025-05-12
US20230374021A1 (en) 2023-11-23
EP4139309A1 (en) 2023-03-01
CN115485277B (zh) 2024-05-14
TW202206432A (zh) 2022-02-16
WO2021213800A1 (en) 2021-10-28
HRP20250426T1 (hr) 2025-06-06
EP4139309B9 (en) 2025-09-10
IL297490B2 (en) 2025-10-01
KR20230005263A (ko) 2023-01-09
UA130588C2 (uk) 2026-03-25
CN118388494A (zh) 2024-07-26
SI4139309T1 (sl) 2025-03-31
CN118388495A (zh) 2024-07-26
KR20250016507A (ko) 2025-02-03
IL320477A (en) 2025-06-01
CN115485277A (zh) 2022-12-16
PH12022552745A1 (en) 2024-03-25
TWI913256B (zh) 2026-02-01
CL2022002579A1 (es) 2023-05-19
DK4139309T3 (da) 2025-04-28
FI4139309T3 (fi) 2025-03-04
US20210332054A1 (en) 2021-10-28
ES3013860T9 (en) 2025-10-28
AU2021260721A1 (en) 2022-09-15
CO2022015054A2 (es) 2023-02-16
ECSP22072777A (es) 2022-10-31
DK4139309T5 (da) 2025-10-27
AU2021260721B2 (en) 2026-05-28
CA3173602A1 (en) 2021-10-28
CN118388490A (zh) 2024-07-26
CR20220537A (es) 2022-12-06
PE20230827A1 (es) 2023-05-19

Similar Documents

Publication Publication Date Title
JP7260723B2 (ja) ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
JP7626774B2 (ja) ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
WO2021156178A1 (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
EA047617B1 (ru) [1,3]ДИАЗИНО[5,4-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ HER2
HK40122799A (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
BR112022021514B1 (pt) [1,3]diazino[5,4-d]pirimidinas como inibidores de her2
HK40081106B (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
HK40081106A (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PJ0202 Trial for correction

St.27 status event code: A-5-5-V10-V11-apl-PJ0202

V11 Administrative appeal requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V11-APL-PJ0202 (AS PROVIDED BY THE NATIONAL OFFICE)

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20260528

Appeal event data comment text: Appeal Kind Category : Correction, Appeal Ground Text : 2759974

Appeal request date: 20260326

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2026105000019

V15 Decision substituted

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2026105000019; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : CORRECTION

P19 Errors in documents containing ipogçös decisions corrected

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P19-OTH-PG1701 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20260618

Republication note text: Request for Public Notice of Correction Statement

Gazette number: 1027599740000

Gazette reference publication date: 20250124